CytomX Therapeutics, Inc. (CTMX)

NMS – Цена в реальном времени. Валюта: USD

3.40

+0.13 (3.98%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

3.39

-0.01 (-0.29%)

После закрытия: Jun 26, 2026, 6:36 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

CytomX Therapeutics, Inc. (CTMX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics: Cashed Up With Catalysts Ahead

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

Видео

No Data

Пресс-релизы

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Search stocks

CytomX Therapeutics, Inc. (CTMX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics: Cashed Up With Catalysts Ahead

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

Видео

No Data

Пресс-релизы

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants